Doxorubicin Hydrochloride This page contains brief information about doxorubicin hydrochloride and a collection of links to more information about the use of this drug, related research results, and ongoing clinical trials. US Brand Name(s): | | Adriamycin RDF | | | | Adriamycin PFS | | | FDA Approved: | | Yes |
Doxorubicin hydrochloride is approved by the Food and Drug Administration (FDA) to treat the following types of cancer:
Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery. In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer. Doxorubicin hydrochloride is also available in a different form called doxorubicin hydrochloride liposome. For more information, see the Drug Information Summary for Doxorubicin Hydrochloride Liposome. Information from the NCIDefinition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Clinical Trial Results: Taxane Combinations Marginally Better than Anthracyclines for Metastatic Breast Cancer (05/21/2008) - Important clinical trial results for this drug, background information, and how the trial was done.
Clinical Trial Results: Anthracyclines Improve Survival for HER2-Positive, But Not HER2-Negative, Breast Cancer (01/30/2008) - Important clinical trial results for this drug, background information, and how the trial was done.
Clinical Trial Results: Positron Emission Tomography (PET) Can Strongly Predict Likelihood of Early Relapse in Hodgkin Lymphoma (08/10/2007) - Important clinical trial results for this drug, background information, and how the trial was done.
Clinical Trial Results: Less-Intense Chemotherapy Effective in Children with Intermediate-Risk Neuroblastoma (06/13/2007) - Important clinical trial results for this drug, background information, and how the trial was done.
Clinical Trial Results: Lower-Toxicity Treatment Effective in Some Cases of Early-Stage Hodgkin Lymphoma (07/10/2006) - Important clinical trial results for this drug, background information, and how the trial was done.
Clinical Trial Results: Rituximab Benefits Younger Lymphoma Patients with Good-Prognosis Diffuse Large-B-Cell Lymphoma (05/03/2006) - Important clinical trial results for this drug, background information, and how the trial was done.
Clinical Trial Results: Age and Type of Chemotherapy Affect Women's Chances of Menstruating after Breast Cancer Treatment (02/27/2006) - Important clinical trial results for this drug, background information, and how the trial was done.
Clinical Trial Results: Chemotherapy Better than Whole-Abdominal Radiation for Advanced Endometrial Cancer
(12/21/2005) - Important clinical trial results for this drug, background information, and how the trial was done.
Clinical Trial Results: Heart Risks of Doxorubicin Higher Than Previously Reported (05/28/2003) - Important clinical trial results for this drug, background information, and how the trial was done.
Clinical Trial Results: Additional Taxol, But Not Higher Dose of Doxorubicin, Helps with Early Breast Cancer
(03/05/2003) - Important clinical trial results for this drug, background information, and how the trial was done.
Information from the National Library of Medicine (NLM)
MedlinePlus Information on Doxorubicin Hydrochloride - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This NLM patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied. Clinical TrialsClinical Trials for Doxorubicin Hydrochloride - Check for trials from NCI's PDQ Cancer Clinical Trials Registry now accepting patients.
Important: The drug information on this Web page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
Back to Top |